Beta-blockers in dermatology

Prabha, Neel; Chhabra, Namrata; Arora, R

doi:10.4103/ijdvl.ijdvl_220_16

Cited by 16 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral b-blockers might be useful to treat persistent erythema and flushing because they antagonize the effects of sympathetic nerve stimulation and circulating catecholamines at b-adrenoceptors [42][43][44]. In a systematic review including nine studies, Logger and colleagues concluded that oral nonselective b-blockers, especially carvedilol and propranolol, may be an effective treatment option for rosacea-associated facial flushing and erythema [43].…”

Section: Oral Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

Section: Oral Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Other immunological and some non-immunological adverse cutaneous drug reactions of β-blockers are included in Table I: for atenolol-vasculitis (V), drug-induced lupus erythematosus (DILE), pseudolymphomatous reactions (PR); for acebutolol-lichenoid reactions (LR), DILE, pincer nail diformity (PND); for labetalol-Peyronies disease (PD), LR, DILE; for metoprolol-PND, PD; for propranolol-erythema multiforme, alopecia, PD, LR; for pindolol-LR, DILE; for oxprenolol-oculocutaneous syndrome, LR, DILE; for sotalol-V (60–63).…”

Section: Cutaneous Side - Effects Of β-Blockersmentioning

confidence: 99%

Immunologic adverse reactions of β-blockers and the skin (Review)

Tatu¹,

Elisei²,

Chioncel

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.

show abstract

“…Carvedilol also induced remission within three weeks in two patients with red vulva syndrome, a condition analogous to RSS 6]. More generally, beta blockers have been utilized to treat refractory rosacea, adrenergic urticaria, aquagenic pruritis, erythromelalgia, and other skin disorders with dysesthesia and inflammation [7].…”

Section: Case Discussionmentioning

confidence: 99%